Skip to main content

Clinical Trials to Treat Childhood Astrocytoma

Trials 1-6 of 6

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Status: Active
Location: 17 locations
Ex Vivo Expanded CD34+ Hematopoietic Stem Cells in Combination with Nivolumab for the Treatment of Recurrent, Progressive, or Refractory Pediatric High-grade Glioma
Status: Active
Location: 3 locations
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Active
Location: 2 locations
Intra-arterial Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treating Patients Under 22 Years of Age with Relapsed or Refractory Intracranial Glioma
Status: Active
Location: 2 locations
A Vaccine (RNA-LP) for the Treatment of Recurrent Pediatric High-Grade Glioma and Recurrent Osteosarcoma, RNA PRIME Trial
Status: Active
Location: 2 locations
Testing the Safety, Tolerability and Immunological Effects of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Temporarily Closed to Accrual
Location: 13 locations